Ivarmacitinib in patients with active ankylosing spondylitis: subgroup analysis based on key baseline features from a phase II/III trial.
Clin RheumatolJul 28, 2026 (epub)
Bei Xu, Yini Ke, Liqin Xu et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase II/III randomized controlled trial evaluated the efficacy of ivarmacitinib 4 mg in patients with active ankylosing spondylitis (AS). The study found that at week 12, ASAS20 response rates were significantly higher in the ivarmacitinib group compared to placebo across various subgroups, indicating consistent efficacy across diverse baseline characteristics.
Key findings
- At week 12, ASAS20 response rates were significantly higher in the ivarmacitinib group compared to placebo.
- ASAS5/6 response rates at week 12 were higher in the ivarmacitinib group across all subgroups.
- Greater improvements in BASDAI scores at week 12 were observed in the ivarmacitinib group across multiple subgroups.
- Efficacy outcomes improved through week 24 with continuous ivarmacitinib treatment.
Why it matters
The findings suggest that ivarmacitinib may provide effective treatment options for patients with active ankylosing spondylitis, regardless of demographic or clinical characteristics, potentially improving patient outcomes.